CHU Bordeaux - hôpital Pellegrin
Bordeaux, 33000, France
NCT Number: NCT01555827
A few studies suggest that patients suffering from neurodegenerative diseases (such a multiple sclerosis or Alzheimer's disease (AD)) show decreased thickness of the retinal nerve fiber layer (RNFL), indicating axonal degeneration. High-definition spectral domain optical coherence tomography (SD-OCT), performed without radiation in a few seconds per eye, offers a precise and standardized estimation of this parameter, which could constitute a biomarker for cerebral axonal degeneration. These RNFL deficits might even be the earliest sign of AD, prior to damage of the hippocampal region that impacts memory.
Besides, some associations of AD with some degenerative diseases of the eye (glaucoma, microvascular abnormalities, age-related macular degeneration (AMD)) have also been reported.
It therefore seems interesting to determine whether RNFL thickness, and other ocular parameters, may give some indications for a better detection of AD and cognitive decline in the elderly.
Looking for future studies?
Notify Me50 year and older
All sexes
Interventional
Not applicable
Bordeaux, 33000, France
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Inclusion criteria
for controls:
Exclusion criteria
Exclusion criteria
for all patients :
Additional exclusion criteria for AD cases:
Additional exclusion criteria for controls:
The following examinations will be performed, after pupil dilation:
The following informations will be collected through a standardized questionnaire, administered face-to-face during the inclusion visit, or at the moment of the verification of eligibility criteria:
Time frame: inclusion visit (day0)
Time frame: inclusion visit (day0)
Time frame: inclusion visit (day0)
Time frame: inclusion visit (day0)
Time frame: inclusion visit (day0)
Time frame: inclusion visit (day0)
Time frame: inclusion visit (day0)
Time frame: inclusion visit (day0)
Time frame: inclusion visit (day0)
Time frame: inclusion visit (day 0)
University Hospital, Bordeaux
Other
Acronym: SIGNAL
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05519137
Alzheimer Disease, Alzheimer's Disease
Menands, New York, United States
View Trial DetailsNCT04867616
Alzheimer Disease, Alzheimer's Disease
Fresno, California, United States
View Trial DetailsNCT02947893
Alzheimer Disease, Alzheimer's Disease
Washington D.C., District of Columbia, United States
View Trial DetailsNCT06206824
Abnormalities, Multiple, Alzheimer Disease
Gières, France
View Trial Details